Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran

Case Reports in Neurology

Volumn 8, Issue 3, 2016, Pages 224-228

  Held, Valentin ^a   Eisele, Philipp ^a   Eschenfelder, Christoph C ^b   Szabo, Kristina ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Anticoagulant; Antidote; Dabigatran; Idarucizumab; Intracerebral hemorrhage; Stroke

Indexed keywords

CREATININE; DABIGATRAN; IDARUCIZUMAB;

AGED; ANTICOAGULATION; APHASIA; ARTICLE; ATRIAL FIBRILLATION; BLOOD PRESSURE; BRAIN HEMORRHAGE; CASE REPORT; CEREBROVASCULAR ACCIDENT; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; EUGLOBULIN LYSIS TEST; FEMALE; FOLLOW UP; HEMIPARESIS; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; ISCHEMIC HEART DISEASE; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; THROMBIN TIME; X-RAY COMPUTED TOMOGRAPHY;

EID: 84994107374     PISSN: 1662680X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000452096     Document Type: Article

References (4)

1. Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, et al: Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015;386:680-690.
2. Pollack CV, Reilly PA, Bernstein R, Dubiel R, Eikelboom J, Glund S, et al: Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost 2015;114:198-205.
3. Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al: Idarucizumab for dabigatran reversal. N Engl J Med 2015;373:511-520.
4. Bernstein RA, Pollack CV Jr, Weitz JI, et al: Abstract 213. Effect of idarucizumab on intracranial bleeding in dabigatran-treated patients: initial results from RE-VERSE AD. Presented at the International Stroke Conference 2016, February 17-19, 2016, Los Angeles.